Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

USE OF GLEASON SCORE, PROSTATE SPECIFIC ANTIGEN, SEMINAL VESICLE AND MARGIN STATUS TO PREDICT BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY

BLUTE, MICHAEL L., BERGSTRALH, ERIK J., IOCCA, ANGELO, SCHERER, BETH, ZINCKE, HORST·2001·Journal of Urology

Abstract

PURPOSE: We determine the importance of clinical and pathological variables for predicting biochemical progression in patients after surgery for specimen confined prostate cancer. We developed a simple scoring algorithm for biochemical progression in node negative cases and tested the algorithm performance on an independent group. MATERIALS AND METHODS: Our study included 2,518 patients with pT2N0 or pT3N0 disease treated between 1990 and 1993. Gleason score, preoperative prostate specific antigen (PSA), margin status, extraprostatic extension, seminal vesicle involvement, DNA ploidy and adjuvant treatment were primary variables analyzed univariately. The Cox proportional hazards model was used on 2,000 randomly selected patients to develop a multivariate scoring algorithm for the aforementioned factors to predict biochemical progression-free survival. The final model included Gleason score, preoperative PSA, margin status, seminal vesicle involvement and adjuvant treatment. The prognostic score derived from this model was validated by applying it to the remaining 518 patients. Harrell's measure of concordance (C) was used to compare competing models. RESULTS: For patients who did not receive adjuvant therapy the derived score based on the Cox model coefficient was Gleason +1 (PSA 4 to 10), +2 (PSA 10.1 to 20), +3 (PSA greater than 20), +2 (positive seminal vesicle) and +2 (positive margin). The score was reduced by 4 if adjuvant hormonal therapy was given and by 2 for only adjuvant radiotherapy. The 5-year progression-free survival was 94% for scores less than 5, 60% for 10 and 32% for greater than 12 (C = 0. 718). Applying the score to the independent validation data set (518) resulted in 5-year progression-free survival of 96% for scores less than 5, 53% for 10 and 30% for greater than 12 (C = 0.759). CONCLUSIONS: Progression-free survival determined by the model score group identified a wide range of risk levels for patients with specimen confined prostate cancer. This simple predictive model allows identification of patients at high risk for cancer progression with specimen confined disease who may be targeted for closer surveillance and adjuvant therapy, while those at lower risk may be simply observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00005392-200101000-00030

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 280

Metadata

Authors
BLUTE, M. L., BERGSTRALH, E. J., IOCCA, A., SCHERER, B., & ZINCKE, H.
Venue
Journal of Urology
Published
2001-01
Volume
165
Issue
1
Pages
119-125
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W1997563283
Cited by
280
References
14
FWCI
10.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: USE OF GLEASON SCORE, PROSTATE SPECIFIC ANTIGEN, SEMINAL VESICLE AND MARGIN STATUS TO PREDICT BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. https://app.cochat.ai/papers/10.1097/00005392-200101000-00030
The paper
BLUTE, M. L., BERGSTRALH, E. J., IOCCA, A., SCHERER, B., & ZINCKE, H. (2001). USE OF GLEASON SCORE, PROSTATE SPECIFIC ANTIGEN, SEMINAL VESICLE AND MARGIN STATUS TO PREDICT BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology. https://doi.org/10.1097/00005392-200101000-00030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.